Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

376 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The Tuberculosis Sentinel Research Network (TB-SRN) of the International epidemiology Databases to Evaluate AIDS (IeDEA): protocol for a prospective cohort study in Africa, Southeast Asia and Latin America.
Enane LA, Duda SN, Chanyachukul T, Bolton-Moore C, Navuluri N, Messou E, Mbonze N, McDade LR, Figueiredo MC, Ross J, Evans D, Diero L, Akpata R, Zotova N, Freeman A, Pierre MF, Rupasinghe D, Ballif M, Byakwaga H, de Castro N, Tabala M, Sterling TR, Sohn AH, Fenner L, Wools-Kaloustian K, Poda A, Yotebieng M, Huebner R, Marcy O; International epidemiology Databases to Evaluate AIDS. Enane LA, et al. Among authors: sterling tr. BMJ Open. 2024 Jan 9;14(1):e079138. doi: 10.1136/bmjopen-2023-079138. BMJ Open. 2024. PMID: 38195167 Free PMC article.
Pharmacogenetics of tuberculosis treatment toxicity and effectiveness in a large Brazilian cohort.
Amorim G, Jaworski J, Yang J, Cordeiro-Santos M, Kritski AL, Figueiredo MC, Turner M, Andrade BB, Velez Edwards DR, Santos AR, Rolla VC, Sterling TR, Haas DW; Regional Prospective Observational Research in Tuberculosis (RePORT)-Brazil network. Amorim G, et al. Among authors: sterling tr. Pharmacogenet Genomics. 2025 Feb 1;35(2):55-64. doi: 10.1097/FPC.0000000000000552. Epub 2024 Oct 15. Pharmacogenet Genomics. 2025. PMID: 39470346
The effect of previous SARS-CoV-2 infection on systemic immune responses in individuals with tuberculosis.
Xavier MS, Araujo-Pereira M, de Oliveira QM, Sant'Anna FM, Ridolfi FM, de Andrade AMS, Figueiredo MC, Sterling TR, Gordhan BG, Kana BD, Andrade BB, Rolla VC, Gomes-Silva A. Xavier MS, et al. Among authors: sterling tr. Front Immunol. 2024 Jun 27;15:1357360. doi: 10.3389/fimmu.2024.1357360. eCollection 2024. Front Immunol. 2024. PMID: 38994357 Free PMC article.
Isoniazid Monoresistance and Antituberculosis Treatment Outcome in Persons With Pulmonary Tuberculosis in Brazil.
Araújo-Pereira M, Arriaga MB, Carvalho ACC, Spener-Gomes R, Schmaltz CAS, Nogueira BMF, Figueiredo MC, Turner MM, Cordeiro-Santos M, Rolla VC, Sterling TR, Andrade BB, Kritski AL; Regional Prospective Observational Research for Tuberculosis (RePORT)-Brazil Consortium. Araújo-Pereira M, et al. Among authors: sterling tr. Open Forum Infect Dis. 2024 Jan 8;11(1):ofad691. doi: 10.1093/ofid/ofad691. eCollection 2024 Jan. Open Forum Infect Dis. 2024. PMID: 38221983 Free PMC article.
Prediction Models for Adverse Drug Reactions During Tuberculosis Treatment in Brazil.
Ridolfi F, Amorim G, Peetluk LS, Haas DW, Staats C, Araújo-Pereira M, Cordeiro-Santos M, Kritski AL, Figueiredo MC, Andrade BB, Rolla VC, Sterling TR; Regional Prospective Observational Research in Tuberculosis (RePORT)–Brazil Consortium. Ridolfi F, et al. Among authors: sterling tr. J Infect Dis. 2024 Mar 14;229(3):813-823. doi: 10.1093/infdis/jiae025. J Infect Dis. 2024. PMID: 38262629 Free PMC article.
Estimating optimal therapeutic drug levels of anti-tuberculosis medications based on treatment safety and effectiveness.
Amorim G, Haas DW, Cordeiro-Santos M, Kritski AL, Figueiredo MC, Staats C, Hachey B, Turner M, Andrade BB, Rolla VC, Sterling TR; Regional Prospective Observational Research in Tuberculosis (RePORT)-Brazil network. Amorim G, et al. Among authors: sterling tr. medRxiv [Preprint]. 2024 Aug 31:2024.08.30.24312723. doi: 10.1101/2024.08.30.24312723. medRxiv. 2024. PMID: 39252925 Free PMC article. Preprint.
Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis.
Dorman SE, Johnson JL, Goldberg S, Muzanye G, Padayatchi N, Bozeman L, Heilig CM, Bernardo J, Choudhri S, Grosset JH, Guy E, Guyadeen P, Leus MC, Maltas G, Menzies D, Nuermberger EL, Villarino M, Vernon A, Chaisson RE; Tuberculosis Trials Consortium. Dorman SE, et al. Am J Respir Crit Care Med. 2009 Aug 1;180(3):273-80. doi: 10.1164/rccm.200901-0078OC. Epub 2009 Apr 30. Am J Respir Crit Care Med. 2009. PMID: 19406981 Clinical Trial.
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, Hackman J, Hamilton CD, Menzies D, Kerrigan A, Weis SE, Weiner M, Wing D, Conde MB, Bozeman L, Horsburgh CR Jr, Chaisson RE; TB Trials Consortium PREVENT TB Study Team. Sterling TR, et al. N Engl J Med. 2011 Dec 8;365(23):2155-66. doi: 10.1056/NEJMoa1104875. N Engl J Med. 2011. PMID: 22150035 Free article. Clinical Trial.
376 results